The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics of VIP943 monotherapy in patients with advanced CD123+ hematologic malignancies.
 
Stephen Anthony Strickland
Consulting or Advisory Role - Abbvie; BerGenBio; Genentech; Kura Oncology; Syros Pharmaceuticals
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); ECOG-ACRIN (Inst); Jazz Pharmaceuticals (Inst); Karyopharm Therapeutics (Inst); Kura Oncology (Inst); Menarini (Inst); PrECOG (Inst); Vincerx Pharma (Inst)
 
Emily K. Curran
Honoraria - CE Synergy; Duke University; Pfizer; SERVIER; University of Chicago
Consulting or Advisory Role - Incyte; Jazz Pharmaceuticals; Kite, a Gilead company; Kite/Gilead
Speakers' Bureau - Clinical Care Options
Travel, Accommodations, Expenses - American Society of Hemotology; CE Synergy; Creative Educational Concepts; Creative Educational Concepts; Dava Oncology; Duke University; Kite/Gilead; Society of Hematologic Oncology; University of Chicago
 
Omer Hassan Jamy
No Relationships to Disclose
 
Mary-Elizabeth Percival
Research Funding - Vincerx Pharma (Inst)
 
Amy J. Johnson
Employment - Vincerx Pharma
Stock and Other Ownership Interests - JJ Innovative Medicine; Vincerx Pharma
Patents, Royalties, Other Intellectual Property - Vincerx Pharma
 
Joseph Birkett
Employment - Aura Biosceinces (I); Centessa Pharmaceuticals (I); Vincerx Pharma
Stock and Other Ownership Interests - Aura Biosciences; Centessa Pharmaceuticals (I); Vincerx Pharma
Consulting or Advisory Role - Aura Biosciences; Ellipses Pharma; Kura Oncology
Travel, Accommodations, Expenses - Aura Biosciences
 
Xin Huang
Employment - Vincerx Pharma
Stock and Other Ownership Interests - Vincerx Pharma
 
Melanie M. Frigault
Employment - AstraZeneca; Vincerx Pharma, Inc.
Stock and Other Ownership Interests - Vincerx Pharma, Inc.
Honoraria - DeciBio
Patents, Royalties, Other Intellectual Property - MET mutation that confers sensitivity to a selective MET inhibitor
Travel, Accommodations, Expenses - Vincerx Pharma, Inc.
 
Hans-georg Lerchen
Employment - Vincerx Pharma GmbH
Leadership - Vincerx Pharma GmbH
Stock and Other Ownership Interests - Bayer; Vincerx Pharma
Research Funding - Vincerx Pharma
 
Beatrix Stelte-Ludwig
Employment - Centessa Pharmaceuticals (I); Vincerx Pharma
Leadership - Vincerx Pharma
Stock and Other Ownership Interests - Vincerx Pharma; Vincerx Pharma (I)
Patents, Royalties, Other Intellectual Property - Bayer; Vincerx Pharma
 
Tasheda Navarro
Employment - Vincerx Pharma
Stock and Other Ownership Interests - Vincerx Pharma
 
Jim Peck
Employment - Vincerx Pharma
Stock and Other Ownership Interests - Lilly; Vincerx Pharma
 
Wyatt Gross
Employment - Vincerx Pharma
Stock and Other Ownership Interests - Vincerx Pharma
 
Raquel Izumi
Employment - Vincerx Pharma
Leadership - Vincerx Pharma
Stock and Other Ownership Interests - Vincerx Pharma
Patents, Royalties, Other Intellectual Property - Acerta Pharma
 
Ahmed M. Hamdy
Employment - Vincerx Pharma
Leadership - Vincerx Pharma
Stock and Other Ownership Interests - Vincerx Pharma
Patents, Royalties, Other Intellectual Property - acalabrutinib multiple patents; multiple patents
 
Naval Guastad Daver
Consulting or Advisory Role - Abbvie; Agios; Amgen; Arog; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Gilead Sciences; Immunogen; Jazz Pharmaceuticals; Kite, a Gilead company; Novartis; Pfizer; SERVIER; Shattuck Labs; Stemline/Menarini; Syndax; Trillium Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); FATE Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Hanmi (Inst); Immunogen (Inst); Kite, a Gilead company (Inst); Novimmune (Inst); Pfizer (Inst); Servier (Inst); Trillium Therapeutics (Inst); Trovagene (Inst)